1. United States of America Stocks

  2. •

    Industrials

  3. •

    Specialty Business Services
Proto Script Pharmaceutical Corp.

Proto Script Pharmaceutical Corp.

PSCR
Proto Script Pharmaceutical Corp.US flagOther OTC
0.00
USD
- -
- -
9,828.00Market Cap
Proto Script Pharmaceutical Corp.
PSCR
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2015
2016
2016
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
0.01
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
-0.02
-0.1
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
-0.01
-0.02
-0.1
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
-0.02
Tangible Book Value per Share
- -
28
30
30
30
300
30
316
83
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
1
- -
1
1
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-16.64
- -
-37.78
-160.49
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
-7
-8
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-16.48
- -
-910.4
-1,386.22
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
-1
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
May'16
Jun'17
Sep'17
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
30
49
49
Market Capitalization
1
7
3

Working Capital

FRC

•

in mil. unless spec.
May'16
Jun'17
Sep'17
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
1
2
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-766.06%
314.91%
Free Cash Flow
- -
-104.83%
-175.58%
Net Income, GAAP
- -
4,350.46%
21,571.91%
Sales/Revenue/Turnover
- -
- -
-10.49%
Total Cash Common Dividend
- -
- -
-33.95%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
1
2016
- -
- -
- -
- -
1
2017
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
-0.02
2017
- -
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2015
- -
- -
- -
- -
- -
2016
- -
- -
- -
- -
- -
2017
- -
- -
- -
- -
- -
Similar Companies
eCargo Holdings Limited (ECG.AX)
Serco Group plc (SECCF)
Honyaku Center Inc. (2483.T)
Cass Information Systems, Inc. (CASS)
Dai Nippon Printing Co., Ltd. (7912.T)
Xinhua News Media Holdings Limited (0309.HK)
Business
Proto Script Pharmaceutical Corp. (Ticker: PSCR) develops and markets pharmaceutical products focused on home healthcare solutions, including prescription medications, over-the-counter remedies, and specialized formulations for chronic condition management; medical devices such as inhalers, injectors, and monitoring kits; and related services like patient adherence programs and telehealth consultations. The company operates primarily in North America, with distribution networks across the United States and Canada, targeting healthcare providers, pharmacies, and direct-to-consumer channels. Founded in 2012 and headquartered in Richmond, Virginia, Proto Script Pharmaceutical Corp. maintains a lean structure with no major subsidiaries or parent affiliations. In late 2024, the company announced a strategic rebranding initiative to emphasize its home care focus, aligning with expanded service offerings under the PSP HomeCare brand, and completed a Series B funding round raising $25 million to support new product launches in respiratory and diabetes care segments. This followed a key partnership with a major pharmacy benefit manager in early 2025, enhancing market access, and the acquisition of a small biotech firm specializing in generic injectables to bolster its portfolio amid growing demand for affordable home-based therapies.